{"groups":[{"description":"Patients received Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.\n\nAvelumab: anti-PDL1 antibody","id":"FG000","title":"Avelumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"21"}],"type":"Relapse/progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"comment":"Of the 35 patients registered on the trial, only 32 actually started treatment.","groupId":"FG000","numSubjects":"32"}],"type":"STARTED"},{"achievements":[{"comment":"16 patients completed cycle 3 with disease assessments done and so were evaluable","groupId":"FG000","numSubjects":"16"}],"comment":"Patients had to reach the CT scan assessment for cycle 3 to be evaluable for the trial","type":"Completed Cycle 3"},{"achievements":[{"comment":"10 patients completed cycle 6, 9 disease assessments done, one disease assessment not done","groupId":"FG000","numSubjects":"10"}],"type":"Completed Cycle 6"},{"achievements":[{"comment":"6 patients completed cycle 8, 4 disease assessments done, 2 disease assessments not done","groupId":"FG000","numSubjects":"6"}],"type":"Completed Cycle 8"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"26"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Of 35 enrolled patients, only 32 started treatment. Of the 3 patients who did not start treatment, one died, one relapsed and one was found to be ineligible post registration.","recruitmentDetails":"Patient were recruited from November 14, 2017 to November 18, 2019 at 14 UK (United Kingdom) hospitals by clinician referral. The first patient was recruited on December 8, 2017, and the final patient recruited on November 18, 2019."}